Comparison of the effectiveness of risperidone and aripiprazole in controlling aggression in inpatient adolescents with conduct disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210718051932N1

Enrollment

Registered

2021-07-25

Start date

2021-07-31

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Conduct disorder. Conduct disorders

Interventions

Intervention 1: Intervention group 1: This group starts treatment with a dose of 1 mg of risperidone and then gradually increases the dose of risperidone to 4 mg due to patient tolerance and no drug s

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: Conduct disorder by criteria DSM5 Age 10-12 years old Patient admitted to the psychiatric ward

Exclusion criteria

Exclusion criteria: Bipolar disorder Suicidal idea Psychotic disorder Drug allergy to risperidon or aripiprazol Severe medical problems

Design outcomes

Primary

Measure	Time frame
Aggression. Timepoint: At the end of 1, 2, 4, 6 weeks,. Method of measurement: Bass and Perry Clinical Global Impression scale (CGI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Mahmoudi Ghara

University of social welfare and rehabilitation sciences

af2mahmoudi@gmail.com+98 21 2297 7263

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026